Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
NCT04093167 · View on ClinicalTrials.gov ↗
Study Summary
The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pembrolizumab before they feel worse, or the cancer is worse on imaging tests. Researchers are studying how levels of these biomarkers can show how cancers are responding to treatment and whether adding chemotherapy to pembrolizumab based on detection of ctDNA can offer better results.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (10)
Ontario
- Health Sciences North — Greater Sudbury
- Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton
- Kingston Health Sciences Centre — Kingston
- Ottawa Hospital Research Institute — Ottawa
- Algoma District Cancer Program — Sault Ste. Marie
- University Health Network — Toronto
Illinois
- The University of Chicago Medical Center — Chicago
Maryland
- The Sidney Kimmel Comprehensive Cancer Centre — Baltimore
British Columbia
- BCCA - Vancouver — Vancouver
Quebec
- The Jewish General Hospital — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2020-05-26 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04093167
The ClinicalTrials.gov registry entry for NCT04093167 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Canadian Cancer Trials Group, which has 102 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention — of which Pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04093167 reports 10 study locations spanning 5 distinct geographic areas — top geographies include Ontario, Illinois, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04093167 about?
NCT04093167 is a clinical study titled "Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer". The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pe...
What is the current status of trial NCT04093167?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2020-05-26. Estimated completion is 2027-07-30.
What conditions does trial NCT04093167 study?
This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04093167?
The interventions under investigation include: Pembrolizumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04093167?
This trial is sponsored by Canadian Cancer Trials Group, which has 102 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04093167 being conducted?
This trial has 10 study locations across Illinois, Maryland, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.